Needham & Company LLC reissued their hold rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a report published on Wednesday morning, AnalystRatings.com reports.
Several other analysts have also recently commented on BCRX. HC Wainwright restated a buy rating and set a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Thursday, October 31st. Zacks Investment Research cut shares of BioCryst Pharmaceuticals from a hold rating to a sell rating in a research note on Thursday, August 8th. BidaskClub cut shares of BioCryst Pharmaceuticals from a sell rating to a strong sell rating in a research note on Friday, October 4th. Finally, ValuEngine cut shares of BioCryst Pharmaceuticals from a buy rating to a hold rating in a research note on Monday, November 4th. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of Hold and an average price target of $9.64.
Shares of NASDAQ:BCRX traded down $0.03 during trading hours on Wednesday, hitting $2.03. The company’s stock had a trading volume of 1,337,600 shares, compared to its average volume of 1,473,949. The company has a market capitalization of $224.19 million, a price-to-earnings ratio of -2.07 and a beta of 1.86. BioCryst Pharmaceuticals has a 52 week low of $1.95 and a 52 week high of $9.95. The company has a debt-to-equity ratio of 2.38, a current ratio of 1.44 and a quick ratio of 1.43. The firm’s fifty day moving average price is $2.53 and its 200 day moving average price is $3.71.
A number of hedge funds and other institutional investors have recently made changes to their positions in BCRX. BlackRock Inc. lifted its stake in shares of BioCryst Pharmaceuticals by 2.6% in the 2nd quarter. BlackRock Inc. now owns 8,925,891 shares of the biotechnology company’s stock valued at $33,831,000 after purchasing an additional 228,525 shares during the period. University of Notre Dame DU Lac acquired a new position in BioCryst Pharmaceuticals during the second quarter worth $1,854,000. Invesco Ltd. raised its position in BioCryst Pharmaceuticals by 63.9% during the second quarter. Invesco Ltd. now owns 1,446,732 shares of the biotechnology company’s stock worth $5,483,000 after acquiring an additional 563,822 shares during the period. DekaBank Deutsche Girozentrale raised its position in BioCryst Pharmaceuticals by 63.6% during the second quarter. DekaBank Deutsche Girozentrale now owns 63,000 shares of the biotechnology company’s stock worth $229,000 after acquiring an additional 24,500 shares during the period. Finally, Morgan Stanley raised its position in BioCryst Pharmaceuticals by 285.1% during the second quarter. Morgan Stanley now owns 1,412,653 shares of the biotechnology company’s stock worth $5,354,000 after acquiring an additional 1,045,869 shares during the period. Institutional investors and hedge funds own 90.67% of the company’s stock.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.
Recommended Story: Outstanding Shares
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.